Caribou Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $12.00K, a 100.00% increase year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $9.00K.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $6.00K, a 95.35% decline year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $129.00K, a 45.34% decline year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $6.00K, a 99.03% decline from fiscal 2024.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $618.00K, a 22.07% decline from fiscal 2023.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $793.00K, a 47.03% decline from fiscal 2022.
- Caribou Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.50M, a 41.32% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $12.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $9.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $6.00K 10-K · filed 2026-03-05 | |
| 2025-06-30 | $6.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $618.00K 10-K · filed 2026-03-05 | |
| 2024-06-30 | $129.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $489.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $793.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $372.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $236.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $115.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.50M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $654.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $363.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $629.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $2.55M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $961.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $566.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $564.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $270.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $139.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $21.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $217.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |